Dysglycemia in adults at risk for or living with non-insulin treated type 2 diabetes: Insights from continuous glucose monitoring

Simple item page
dc.citation.articleNumber100853en_US
dc.citation.journalTitleEClinicalMedicineen_US
dc.citation.volumeNumber35en_US
dc.contributor.authorBarua, Souptiken_US
dc.contributor.authorSabharwal, Ashutoshen_US
dc.contributor.authorGlantz, Naminoen_US
dc.contributor.authorConneely, Caseyen_US
dc.contributor.authorLarez, Ariannaen_US
dc.contributor.authorBevier, Wendyen_US
dc.contributor.authorKerr, Daviden_US
dc.date.accessioned2021-06-07T20:22:20Zen_US
dc.date.available2021-06-07T20:22:20Zen_US
dc.date.issued2021en_US
dc.description.abstractBackground: Continuous glucose monitoring (CGM) has demonstrable benefits for people living with diabetes, but the supporting evidence is almost exclusively from White individuals with type 1 diabetes. Here, we have quantified CGM profiles in Hispanic/Latino adults with or at-risk of non-insulin treated type 2 diabetes (T2D). Methods: 100 participants (79 female, 86% Hispanic/Latino [predominantly Mexican], age 54·6 [±12·0] years) stratified into (i) at risk of T2D, (ii) with pre-diabetes (pre-T2D), and (iii) with non-insulin treated T2D, wore blinded CGMs for 2 weeks. Beyond standardized CGM measures (average glucose, glucose variability, time in 70–140 mg/dL and 70–180 mg/dL ranges), we also examined additional CGM measures based on the time of day. Findings: Standardized CGM measures were significantly different for participants with T2D compared to at-risk and pre-T2D participants (p<0·0001). In addition, pre-T2D participants spent more time between 140 and 180 mg/dL during the day than at-risk participants (p<0·01). T2D participants spent more time between 140 and 180 mg/dL both during the day and overnight compared to at-risk and pre-T2D participants (both p<0·0001). Time in 70–140 mg/dL range during the day was significantly correlated with HbA1c (r=-0·72, p<0·0001), after adjusting for age, sex, BMI, and waist circumference (p<0·0001). Interpretation: Standardized CGM measures show a progression of dysglycemia from at-risk of T2D, to pre-T2D, and to T2D. Stratifying CGM readings by time of day and the range 140–180 mg/dL provides additional metrics to differentiate between the groups. Funding US Department of Agriculture (Grant #2018-33800-28404) and NSF PATHS-UP ERC (Award #1648451).en_US
dc.identifier.citationBarua, Souptik, Sabharwal, Ashutosh, Glantz, Namino, et al.. "Dysglycemia in adults at risk for or living with non-insulin treated type 2 diabetes: Insights from continuous glucose monitoring." <i>EClinicalMedicine,</i> 35, (2021) Elsevier: https://doi.org/10.1016/j.eclinm.2021.100853.en_US
dc.identifier.digital1-s2-0-S2589537021001334-mainen_US
dc.identifier.doihttps://doi.org/10.1016/j.eclinm.2021.100853en_US
dc.identifier.urihttps://hdl.handle.net/1911/110666en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsThis is an open access article under the CC BY-NC-ND licenseen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.titleDysglycemia in adults at risk for or living with non-insulin treated type 2 diabetes: Insights from continuous glucose monitoringen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2-0-S2589537021001334-main.pdf
Size:
1.46 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
ECE Publications